ADVFN Logo ADVFN

We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now

Toplists

It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Hot Features

Registration Strip Icon for pro Trade like a pro: Leverage real-time discussions and market-moving ideas to outperform.
Gritstone bio Inc

Gritstone bio Inc (GRTS)

0.7608
-0.0212
(-2.71%)
Closed June 17 4:00PM
0.7505
-0.0103
( -1.35% )
Pre Market: 8:00AM

Your Hub for Real-Time streaming quotes, Ideas and Live Discussions

Key stats and details

Current Price
0.7505
Bid
0.7505
Ask
0.76
Volume
10,065
0.00 Day's Range 0.00
0.6716 52 Week Range 3.33
Market Cap
Previous Close
0.7608
Open
-
Last Trade
13
@
0.7607
Last Trade Time
08:03:37
Financial Volume
-
VWAP
-
Average Volume (3m)
2,891,974
Shares Outstanding
98,065,594
Dividend Yield
-
PE Ratio
-0.54
Earnings Per Share (EPS)
-1.41
Revenue
16.34M
Net Profit
-138.49M

About Gritstone bio Inc

Gritstone Bio Inc is a biotechnology company. The company is engaged in developing personalized cancer immunotherapies to fight multiple cancer types and infectious diseases. It is building a pipeline of Immunotherapies product candidates for patients with solid tumors, which includes GRANITE, SLATE... Gritstone Bio Inc is a biotechnology company. The company is engaged in developing personalized cancer immunotherapies to fight multiple cancer types and infectious diseases. It is building a pipeline of Immunotherapies product candidates for patients with solid tumors, which includes GRANITE, SLATE, BiSAb, among others. Show more

Sector
Biological Pds,ex Diagnstics
Industry
Biological Pds,ex Diagnstics
Headquarters
Wilmington, Delaware, USA
Founded
1970
Gritstone bio Inc is listed in the Biological Pds,ex Diagnstics sector of the NASDAQ with ticker GRTS. The last closing price for Gritstone bio was $0.76. Over the last year, Gritstone bio shares have traded in a share price range of $ 0.6716 to $ 3.33.

Gritstone bio currently has 98,065,594 shares outstanding. The market capitalization of Gritstone bio is $74.53 million. Gritstone bio has a price to earnings ratio (PE ratio) of -0.54.

GRTS Latest News

The Gross Law Firm Reminds Gritstone bio, Inc. Investors of the Pending Class Action Lawsuit with a Lead Plaintiff Deadline of August 6, 2024 - GRTS

The Gross Law Firm Reminds Gritstone bio, Inc. Investors of the Pending Class Action Lawsuit with a Lead Plaintiff Deadline of August 6, 2024 - GRTS PR Newswire NEW YORK, June 17, 2024 NEW YORK...

Gritstone bio Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

EMERYVILLE, Calif., June 13, 2024 (GLOBE NEWSWIRE) -- Gritstone bio, Inc. (Nasdaq: GRTS), a clinical-stage biotechnology company that aims to develop the world’s most potent vaccines, today...

Gritstone bio to Participate in Upcoming Investor and Scientific Conferences

EMERYVILLE, Calif., June 04, 2024 (GLOBE NEWSWIRE) -- Gritstone bio, Inc. (Nasdaq: GRTS), a clinical-stage biotechnology company working to develop the world’s most potent vaccines, today...

PeriodChangeChange %OpenHighLowAvg. Daily VolVWAP
10.02052.808219178080.730.830.72356365240.78982253CS
4-0.0695-8.47560975610.820.8550.70113902360.77864419CS
12-1.9895-72.60948905112.742.940.671628919741.03769093CS
26-1.1995-61.51282051281.953.170.671624818921.67531481CS
52-1.4495-65.88636363642.23.330.671620557661.79731771CS
156-8.9595-92.27085478899.7114.420.671614172643.78637625CS
260-9.8795-92.939793038610.6334.670.671611289346.4526986CS

Market Movers

View all
  • Most Active
  • % Gainers
  • % Losers
SymbolPriceVol.
NLSPNLS Pharmaceutics Ltd
$ 0.3851
(159.68%)
95.58M
ASNSActelis Networks Inc
$ 2.73
(137.39%)
18.15M
RELIReliance Global Group Inc
$ 0.49
(120.72%)
4.97M
SNOASonoma Pharmaceuticals Inc
$ 0.2788
(65.46%)
40.16M
MLGOMicroAlgo Inc
$ 5.11
(43.94%)
7.39M
STISolidion Technology Inc
$ 0.5491
(-71.55%)
2.7M
DMTKDermTech Inc
$ 0.1371
(-58.77%)
705.39k
AWINAERWINS Technologies Inc
$ 1.51
(-54.79%)
79.34k
BIOLBiolase Inc
$ 0.0868
(-41.59%)
7.22M
QMCOQuantum Corporation
$ 0.4799
(-38.47%)
170.57k
NLSPNLS Pharmaceutics Ltd
$ 0.3851
(159.68%)
95.58M
MBIOMustang Bio Inc
$ 1.07
(42.67%)
41.58M
SNOASonoma Pharmaceuticals Inc
$ 0.2788
(65.46%)
40.16M
ASNSActelis Networks Inc
$ 2.73
(137.39%)
18.15M
QLGNQualigen Therapeutics Inc
$ 0.226
(29.29%)
16.36M

GRTS Discussion

View Posts
jondoeuk jondoeuk 1 month ago
Still the only company I'm aware of that is able to induce such a rapid, robust and consistent large number of CD8+ T-cells.



But having a strong CD8+ T-cell response is useless without the right selection https://www.science.org/doi/10.1126/scitranslmed.aax7918

EDGE does not specifically model immunogenicity but performs reasonably well at predicting immunogenic peptides (immunogenicity is >50% of mutations per patient generate a detectable CD8+ T-cell response).

CD4+ T-cell responses are important as well (but prediction is a lot harder) https://www.nature.com/articles/s41586-019-1671-8

Also, what setting it is given is equally important. They (vaccines in general) likely offer a greater benefit to the patient if administered in earlier clinical settings, such as the adjuvant setting, for a number of reasons.
👍️0
Monksdream Monksdream 2 months ago
GRTS new 52 lo
👍️0
Tom turtles Tom turtles 3 months ago
And then the offering....classic bs
👍️0
DewDiligence DewDiligence 3 months ago
GRTS—(-40%/AH)—reports purportedly-positive interim phase-2 data:

https://www.globenewswire.com/news-release/2024/04/01/2855416/0/en/Gritstone-bio-Announces-Positive-Preliminary-Progression-free-Survival-and-Long-term-Circulating-Tumor-DNA-ctDNA-Data-from-Phase-2-Portion-of-Ongoing-Phase-2-3-Study-of-its-Persona.html Gritstone bio…today announced positive preliminary data from the ongoing, signal seeking Phase 2 portion of the Phase 2/3 study evaluating GRANITE, its personalized neoantigen cancer vaccine, in front-line metastatic microsatellite stable colorectal cancer (MSS-CRC).

Circulating tumor DNA (ctDNA) analysis over several months of treatment shows the expected relationship with disease progression and favors GRANITE, while short-term ctDNA response analysis (molecular response as defined per protocol) did not demonstrate a difference between study arms. Emphasis added.
👍️0
jondoeuk jondoeuk 3 months ago
The results could be difficult to interpret as Gritstone is primarily evaluating ctDNA, an endpoint that doesn't have the full backing from any regulator that I know of. Gritstone could also report other data, but the company argues that radiographic endpoints aren't as good as ctDNA, which means that the endpoints might not match up.
👍️0
Little Run Little Run 8 months ago
Yep, looking past $3 now…let’s ride!!!😎🍻🍻✌️
👍️0
TrendTrade2016 TrendTrade2016 8 months ago
grts breaking 2.75 trigger
👍️0
TrendTrade2016 TrendTrade2016 8 months ago
GRTS...NEXT STOP 2.75
👍️0
TrendTrade2016 TrendTrade2016 8 months ago
GRTS MONSTER CANCER PLAY
👍️0
TrendTrade2016 TrendTrade2016 8 months ago
GRTS WHAT A MONSTER...LETS SEE 2.46 NEXT
👍️0
TrendTrade2016 TrendTrade2016 8 months ago
GRTS....READY FOR 2.32
👍️0
Little Run Little Run 8 months ago
That’s next…
👍️0
TrendTrade2016 TrendTrade2016 9 months ago
GRTS...I THINK THEY CURED CANCER
👍️0
TrendTrade2016 TrendTrade2016 9 months ago
GRTS READY FOR 2.37
👍️0
RT2GAIN RT2GAIN 9 months ago
Merry Christmas $$$
👍️0
Monksdream Monksdream 9 months ago
GRTS under $2
👍️0
Little Run Little Run 9 months ago
Wow, finally some company. LOL!!! Oncology side is even stronger. Barda $$$ was great though. LFG!!!
👍️0
crudeoil24 crudeoil24 9 months ago
Gritstone Bio shares are trading higher after Piper Sandler maintained an Overweight rating on the stock and raised its price target from $6 to $7. >>>>> GRTS
👍️0
RT2GAIN RT2GAIN 9 months ago
I wonder how many people know that this is a cornovavirus stock company… hmmm
👍️0
RT2GAIN RT2GAIN 9 months ago
Sounds like you're keeping a close eye on this one. Hoping for the best!
👍️0
Wolf of MP Wolf of MP 9 months ago
This is just the appetizer. Shorties going to get roasted once float locks up. Lots of shares sold at these levels. Longs or quick flippers should be rewarded soon
👍️0
TrendTrade2016 TrendTrade2016 9 months ago
GRTS..BREAKING NICELY
👍️0
RT2GAIN RT2GAIN 9 months ago
Merry Christmas $$$
👍️0
Wolf of MP Wolf of MP 9 months ago
They are trying for that cup and handle. Let's goo
👍️0
Wolf of MP Wolf of MP 9 months ago
Getting up for the next leg. Get in or get left behind.

All IMO of course. Trading well, should be trading much better with a $400 mil grant. I suspect some manipulation to take all the shares they can get.
👍️0
TrendTrade2016 TrendTrade2016 9 months ago
GRTS ANOTHER BIO READY
👍️0
crudeoil24 crudeoil24 9 months ago
Share price holding in AH . Let's see how she runs tomorrow.
👍️0
crudeoil24 crudeoil24 9 months ago
Maybe government grants don't count in totaling yearly revenues ! > $$$$$
👍️0
TheFinalCD TheFinalCD 9 months ago
WE ARE LIKE

underpaid news reporters

https://finviz.com/quote.ashx?t=GRTS&p=d
👍️0
sc00pnDump sc00pnDump 9 months ago
Barely anyone is selling, and the shorts disappeared…..



Wow, looks good for tomorrow


Have a great night
👍️0
sc00pnDump sc00pnDump 9 months ago

Latest News

UPDATE 1-Gritstone bio wins $433
million US contract for COVID vaccine study
Sep 27, 2023 at 4:48 p.m. ET
(Adds share price and study details in paragraphs 3-5)
Sept 27 (Reuters) - Gritstone bio on Wednesday secured a $433 million contract by the U.S. government to conduct a mid-stage study of its self-amplifying mRNA COVID-19 vaccine candidate.
The contract is a part of "Project NextGen," an initiative by the U.S. Department of Health and Human Services to advance a pipeline of new, innovative vaccines and therapeutics providing broader and more durable protection against COVID-19 infection.
Gritstone's shares rose 36.1% to $1.61 after the bell.
The study will compare the efficacy, safety and immunogenicity of Gritstone's COVID-19 vaccine candidate with an approved vaccine.
Gritstone plans to initiate the mid-stage study in the first quarter of next year.
The contract was awarded by the Biomedical Advanced Research and Development Authority, a U.S. federal agency that funds disease-fighting technology.
👍️0
weedtrader420 weedtrader420 9 months ago
WOOHOOOOOO WOOHOOOOOO
👍️0
weedtrader420 weedtrader420 9 months ago
Looks like that’s going to change
👍️0
crudeoil24 crudeoil24 9 months ago
Horrible Revenues > According to MarketWatch, GRTS annual revenue averages $11,000. per employee.
👍️0
crudeoil24 crudeoil24 9 months ago
Gritstone bio, Inc. is a biotechnology company. The Company discovers, develops, manufactures and delivers next generation cancer and infectious disease immunotherapy candidates by vaccine vectors, self-amplifying mRNA (samRNA) and chimpanzee adenovirus (ChAd). Its two oncology programs in clinical-stage development are GRANITE, individualized neoantigen-based immunotherapy, and SLATE, an off-the-shelf shared neoantigen-based immunotherapy. It has an infectious disease pipeline, which includes two programs in clinical-stage development: CORAL, a second-generation COVID-19 vaccine program that may have pan-coronavirus potential to protect against future coronavirus pandemics, and an HIV therapeutic/cure vaccine candidate. In oncology, it develops personalized vaccines that aim to destroy tumors through CD8+ (killer) T cell recognition of tumor cells by virtue of their surface display of neoantigens, peptides that are presented on cancer cells when certain mutations occur in tumor DNA.
👍️0
sc00pnDump sc00pnDump 9 months ago
We’ll look shorts are in
👍️0
sc00pnDump sc00pnDump 9 months ago
Lucky I bought after market, let’s see tomorrow what happens


Have a good night
👍️0
weedtrader420 weedtrader420 9 months ago
WOOHOOOOOO
👍️0
sc00pnDump sc00pnDump 9 months ago
Looking great
👍️0
subslover subslover 9 months ago
Gritstone bio Awarded BARDA Contract to Conduct Comparative Phase 2b Study Evaluating Next-Generation Vaccine Candidate for COVID-19 Valued at up to $433 Million
-- 10,000 participant randomized Phase 2b study will evaluate Gritstone’s self-amplifying mRNA (samRNA) vaccine candidate containing Spike plus other viral targets with an approved vaccine against COVID-19 --

-- Contract is part of ‘Project NextGen,’ an initiative by the U.S. Department of Health and Human Services to advance a pipeline of new, innovative vaccines and therapeutics providing broader and more durable protection for COVID-19 --

EMERYVILLE, Calif., Sept. 27, 2023 (GLOBE NEWSWIRE) -- Gritstone bio, Inc. (Nasdaq: GRTS), a clinical-stage biotechnology company working to develop the world’s most potent vaccines, announced today that it was awarded a contract by the Biomedical Advanced Research and Development Authority (BARDA) to conduct a Phase 2b comparative study evaluating Gritstone’s self-amplifying mRNA (samRNA) vaccine candidate containing Spike plus other viral targets to protect against COVID-19. The agreement, which is valued at up to $433 million, was awarded as part of ‘Project NextGen,’ an initiative by the U.S. Department of Health and Human Services (HHS) to advance a pipeline of new, innovative vaccines and therapeutics providing broader and more durable protection for COVID-19.

Under the contract, Gritstone bio will conduct a 10,000 participant, randomized Phase 2b double-blinded study to compare the efficacy, safety, and immunogenicity of the Gritstone next-generation COVID-19 vaccine candidate with an approved COVID-19 vaccine. Preparations for the study are underway, and execution of the study will be fully funded by BARDA. Gritstone will run the study in the United States in collaboration with the COVID-19 Prevention Network (CoVPN), a NIAID-supported network of clinical trial sites based at Fred Hutchinson Cancer Center with experience conducting large COVID-19 vaccine trials.

“We are honored to receive this award from BARDA to advance our next-generation samRNA vaccine against COVID-19 (the CORAL program), which provides strong validation of our innovative vaccine platform in infectious diseases. Not only does this contract supply the necessary resources to advance the development of CORAL, but it also signifies the trust and confidence the U.S. government has placed in our novel vaccine approach,” said Andrew Allen, M.D., Ph.D., Co-founder, President, and Chief Executive Officer of Gritstone bio. “First-generation COVID-19 vaccines provided great utility during the height of the pandemic but are limited in breadth and durability of clinical protection. CORAL was designed to address these limitations by inducing durable neutralizing antibody and T cell-based immunity against current and future SARS-CoV-2 variants. Across multiple Phase 1 studies, our samRNA vaccine, which incorporates both Spike and other viral targets (Spike plus), has demonstrated induction of potent immune responses with potential to drive broad and durable clinical protection – this potential will now be tested in a randomized setting. We are excited about this opportunity to work alongside BARDA and look forward to initiating the Phase 2b study (CORAL-BARDA) in the first quarter of 2024. With CORAL moving into a randomized Phase 2 study alongside our personalized cancer vaccine program (GRANITE), Gritstone now sits at the precipice of unlocking the full potential of our novel vaccine platforms in both oncology and infectious diseases.”

This project has been funded with Federal funds from the Department of Health and Human Services; Office of the Assistant Secretary for Preparedness and Response; Biomedical Advanced Research and Development Authority, under Contract No. 75A50123C00062.

About the CORAL Program
Gritstone’s CORAL program is applying Gritstone’s infectious disease approach for the prevention of COVID-19. The program aims to drive both B cell and T cell immunity using self-amplifying mRNA (samRNA) and novel immunogens containing Spike plus additional viral targets. To date, the CORAL program has comprised three Phase 1 trials evaluating multiple samRNA vaccine candidates across various patient populations and settings: CORAL-BOOST (healthy volunteers following primary series of currently approved COVID-19 vaccines); CORAL-CEPI (vaccine-naïve healthy and HIV+ subjects in South Africa); and CORAL-NIH (run by the National Institute of Allergy and Infectious Disease [NIAID] in previously vaccinated healthy volunteers). Results to date have demonstrated induction and persistence of high neutralizing antibody levels through at least 6 months as well as broad T cell responses. The CORAL program is supported by Biomedical Advanced Research and Development Authority (BARDA), NIAID, the Coalition for Epidemic Preparedness Innovations (CEPI) and the Bill & Melinda Gates Foundation.

About Self-amplifying mRNA (samRNA)
Self-amplifying mRNA (samRNA) is rapidly emerging as a well-tolerated, scalable and widely-applicable platform technology which can be used to develop multiple vaccines simply by changing the sequence of the antigen (the target of the immune system) that is encoded in the vector RNA and delivered in a lipid nanoparticle. Like traditional mRNA vaccines, samRNA vaccines use the host cell’s translation system to convert mRNA to protein target antigens in order to stimulate immunity. Unlike traditional mRNA, samRNA creates multiple copies of the antigen RNA once in the cell, potentially leading to extended duration and magnitude of antigen expression. Gritstone designs novel immunogens, the vaccine regions encoding virus antigens, and includes both Spike antigen (similar to first-generation COVID-19 vaccines) and evolutionarily conserved, non-Spike antigens likely to drive T cell responses in its next-generation COVID-19 vaccines. Potential benefits of this samRNA “Spike plus” approach include (1) strong and durable induction of neutralizing antibodies to Spike, (2) broad and durable T cell immunity (CD4+ and CD8+) to multiple viral proteins, (3) potency at lower doses (dose sparing), and (4) refrigerator stability.

About Gritstone bio
Gritstone bio, Inc. (Nasdaq: GRTS) is a clinical-stage biotechnology company that aims to develop the world’s most potent vaccines. We leverage our innovative vectors and payloads to train multiple arms of the immune system to attack critical disease targets.
👍️0
sc00pnDump sc00pnDump 9 months ago
500 million in funding nice
👍️0
weedtrader420 weedtrader420 9 months ago
GRTS$
👍️0
jondoeuk jondoeuk 1 year ago
AACR PR https://www.globenewswire.com/news-release/2023/04/17/2647754/0/en/Gritstone-bio-Presents-Advances-in-Neoantigen-Prediction-and-Cancer-Vaccine-Immunogenicity-at-the-2023-AACR-Annual-Meeting.html
👍️0
Little Run Little Run 1 year ago
Nice...$$$$!!!????????
👍️0
Little Run Little Run 1 year ago
Nice...$$$$!!!????????
👍️0
Little Run Little Run 1 year ago
Holy Fuck...Still just me!
👍️0
Little Run Little Run 2 years ago
Hey King, yep that’s me!!!
👍️0
Little Run Little Run 2 years ago
Hey King, yep that’s me!!!
👍️0
Little Run Little Run 2 years ago
Well...she ran. Holding every last share and actually added today. Fuck, posting by myself isn’t cool or healthy. But it’s needed for validation of entry’s and exits in my little mind. Join us on Twits, arthura is my deal, but call me Art...Let’s F’n Go!!!!
👍️0
Little Run Little Run 2 years ago
OK. In @$1.78 and it’s time to rip some F’n faces off!!! Let’s Go!!!
👍️0

Your Recent History

Delayed Upgrade Clock